Australian researchers have made a breakthrough in Alzheimer's research, demonstrating what they describe as the first gene therapy-based approach to treating advanced forms of the disease.
Modifying 12 risk factors over the life course could delay or prevent 40% of dementia cases, a new report suggests.
According to this meta-analysis, recently published in Memory & Cognition, music training has no significant effect on cognition.
The novel, orally administered calcitonin gene-related peptide (CGRP) antagonist atogepant has met the primary endpoint
During this Summer we have extended our consultation hours to Wednesdays and Fridays in order to provide better care and reduce waiting lists caused by confinement.
In the last number of Neurology®, a team representing the Aspirin in Reducing Events in the Elderly (ASPREE) study reports the cognitive outcomes from low-dose aspirin (100 mg/d) therapy vs placebo in elderly individuals who were free of cardiovascular disease, physical disability, or diagnosed dementia.
Alzheimer's disease can present clinically with either the typical amnestic phenotype or with atypical phenotypes, such as logopenic progressive aphasia and posterior cortical atrophy.
Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke or transient ischemic attack (TIA). In a previous trial, ticagrelor was not better than aspirin in preventing vascular events or death after stroke or TIA.
In this new article the authors (Kristina Szabo et al. https://doi.org/10.1212/WNL.0000000000009783) analyze how the evidence of hippocampal diffusion-weighted imaging (DWI) lesions may support the clinical diagnosis of transient global amnesia (TGA).
Two early studies are raising hopes that some genetic forms of amyotrophic lateral sclerosis (ALS) can be treated.
